<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899583</url>
  </required_header>
  <id_info>
    <org_study_id>ACOART SCB BIF</org_study_id>
    <nct_id>NCT04899583</nct_id>
  </id_info>
  <brief_title>ACOART SCB BIF: Treatment of Coronary Bifurcation Lesion by Sirolimus Coated Balloon vs Paclitaxel Coated Balloon</brief_title>
  <official_title>A Prospective, Multicenter, Random Controlled Clinical Trail to Evaluate the Effectiveness and Safety of Sirolimus Coated Balloon Versus a Paclitaxel Coated Balloon in the Treatment of Coronary Bifurcation Lesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acotec Scientific Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acotec Scientific Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized controlled trial is to examine the treatment of coronary&#xD;
      bifurcation lesion with a sirolimus coated balloon versus a paclitaxel coated balloon. This&#xD;
      trial is designed as prospective, multicenter, randomized and open-label.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diameter stenosis rate of bifurcation lesion determinated by Digital Substraction Angiography (DSA) at 9 months post procedure.</measure>
    <time_frame>9 months post procedure</time_frame>
    <description>Defined as (1-minimum lumen diameter of target lesion/reference vessel diameter)*100% at 9 months post procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of device success</measure>
    <time_frame>Immediately after procedure</time_frame>
    <description>Defined as the rate of successful delivery and withdrawal of the delivery catheter, and achieving a final in-lesion residual stenosis less than 30% and TIMI flow grade 3 by using the assigned device only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of lesion success</measure>
    <time_frame>Immediately after procedure</time_frame>
    <description>Defined as the rate of achieving a final in-lesion residual stenosis &lt; 30% by visual estimate and TIMI flow grade 3 by using any percutaneous method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of procedure success</measure>
    <time_frame>Immediately after procedure</time_frame>
    <description>Defined as the rate of achieving lesion success without MACE (composite of cardiac death, MI and TLR events) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of target lesion failure (TLF) or device-related composite endpoints (DoCE）</measure>
    <time_frame>30 days, 6 months, 9 months, 12 months post procedure</time_frame>
    <description>Defined as a composite rate of cardiac death, target vessel-related MI, or ischemia-driven TLR events at 30 days, 6 months, 9 months and 12 months post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patient-related composite endpoints (PoCE）</measure>
    <time_frame>30 days, 6 months, 9 months, 12 months post procedure</time_frame>
    <description>Defined as a composite rate of all cause death, all cause-related MI or TLR events at 30 days, 6 months, 9 months and 12 months post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter stenosis rate</measure>
    <time_frame>9 months post procedure</time_frame>
    <description>Defined as the rate of restenosis (&gt;50% diameter stenosis) of main vessel after 9 months at 9 months post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late lumen loss (LLL)</measure>
    <time_frame>9 months post procedure</time_frame>
    <description>Defined as the difference of minimum lumen diameter (MLD) from post procedure to 9 months follow-up, including late lumen loss of main vessel and side branch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic binary restenosis (ABR) rate</measure>
    <time_frame>9 months post procedure</time_frame>
    <description>Defined as the percentage rate of binary restenosis determined by angiographic at 9 months post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of composite safety endpoint</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Defined as a composite rate of all-cause death, cardiogenic death, myocardial infarction, target vessel-related myocardial infarction, incidence of thrombotic events (acute, subacute, late) defined by ARC at 12 months post procedure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Coronary Bifurcation Lesions</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a Sirolimus Coated Balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a Paclitaxel Coated Balloon Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus Coated Balloon Catheter</intervention_name>
    <description>a Sirolimus Coated Balloon Catheter designed and produced by Acotec</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>a Paclitaxel Coated Balloon Catheter</intervention_name>
    <description>a Paclitaxel Coated Balloon Catheter(trade name:Bingo)</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old and ≤75 years old&#xD;
&#xD;
          -  Diagnosed as stable or unstable angina pectoris, asymptomatic myocardial ischemia or&#xD;
             old myocardial infarction, or recent myocardial infarction in stable stage.&#xD;
&#xD;
          -  Eligible for balloon dilatation or stent implantation.&#xD;
&#xD;
          -  Subject (or legal guardian) understands the study requirements and procedures and&#xD;
             provides written Informed Consent before any study tests or procedures are performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AMI occurred within 7 days before operation&#xD;
&#xD;
          -  The subjects had congestive heart failure or the heart function was classified as&#xD;
             NYHA/KillipIV.&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt; 35%&#xD;
&#xD;
          -  History of heart transplantation&#xD;
&#xD;
          -  The subjects had severe arrhythmias, such as high-risk ventricular extrasystole and /&#xD;
             or ventricular tachycardia.&#xD;
&#xD;
          -  The subjects had stroke, gastrointestinal bleeding or active ulcers, or had a high&#xD;
             risk of bleeding in the past 6 months.&#xD;
&#xD;
          -  Active bleeding physique or blood coagulation disorder&#xD;
&#xD;
          -  Known renal insufficiency（eGFR&lt;30ml/min）&#xD;
&#xD;
          -  Contraindicated to anticoagulants or antiplatelet agents&#xD;
&#xD;
          -  Has a history of percutaneous coronary intervention (PCI) within 6 months before&#xD;
             enrollment.&#xD;
&#xD;
          -  Has contraindications for coronary artery bypass grafting&#xD;
&#xD;
          -  known to be allergic to aspirin, heparin, contrast agents, paclitaxel and sirolimus&#xD;
&#xD;
          -  Life expectancy less than 12 months, or unable to complete a 12-month follow-up&#xD;
&#xD;
          -  Pregnant or lactating females, or who plan to become pregnant during a follow-up&#xD;
             period of 1 year after operation&#xD;
&#xD;
          -  The subjects have participated in other drug property studies or device studies that&#xD;
             have not yet completed the main end point.&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          -  One target lesion (bifurcation lesion) in the coronary artery is allowed, and if there&#xD;
             are coexistent non-bifurcated lesions requiring PCI intervention, only one lesion was&#xD;
             accepted at most, and the target lesion should be treated after successful PCI&#xD;
             treatment of non-target lesion.&#xD;
&#xD;
          -  Target Lesion located in native coronary artery must be de novo&#xD;
&#xD;
          -  Medina classification should be (1.1.1, 1.0.1, 0.1.1)&#xD;
&#xD;
          -  Main branch of target lesion (%DS is ≥70% or ≥50% with clinical symptoms ) is suitable&#xD;
             for stent implantation&#xD;
&#xD;
          -  Target Lesion located in main branch should be covered by DES. Moreover, the residual&#xD;
             stenosis ≤ 30%, TIMI flow is 3, no complications and branch vessel opening stenosis ≥&#xD;
             70%.&#xD;
&#xD;
          -  Reference vessel diameter of the branch is 2.0-4.0mm (by visual)&#xD;
&#xD;
          -  Target lesion length ≤ 36mm (by visual)&#xD;
&#xD;
        Angiographic Exclusion Criteria:&#xD;
&#xD;
          -  Target or non-target lesion located in left main&#xD;
&#xD;
          -  Subjects who have non-target lesions of bifurcation&#xD;
&#xD;
          -  The target lesion is trifurcation or multifurcation lesion.&#xD;
&#xD;
          -  Main branch of target lesion located within 3 mm from the ostium of LAD or LCx or RCA&#xD;
&#xD;
          -  The branch lesion is a diffuse long lesion, which could't covered by one DCB.&#xD;
&#xD;
          -  Main or side branch is occlusive lesion, which TIMI flow is 0.&#xD;
&#xD;
          -  Aneurysm existed in the blood vessel at the target lesion&#xD;
&#xD;
          -  Side branch severely calcified or tortuous&#xD;
&#xD;
          -  The blood pressure was too low to tolerate intracoronary injection of ≥ 100ug&#xD;
             nitroglycerin&#xD;
&#xD;
          -  Failure pre-dilatation of the side branch ostium (residual stenosis &gt; 30% ,the blood&#xD;
             flow in TIMI is not up to grade 3, or has dissection of type C or above according to&#xD;
             NHLBI grade)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ge Junbo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lu Hao</last_name>
    <phone>13795211858</phone>
    <email>lu.hao.@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ge Junbo, MD</last_name>
      <phone>021-64041990</phone>
      <email>Ge.junbo@zs_hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

